AERODUO-2NCT07896252
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below.
- Minor Start date changed from estimate of Oct 2026 to Nov 1, 2026
- Site details revised at 1 of 2 sites
- Notable Recruitment opened
- Study sites: 0 to 2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Bronchodilation - FEV1
Timeframe: Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
Bronchodilation - FEV AUC
Timeframe: Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
Bronchodilation - Peak FEV1
Timeframe: Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
Bronchodilation - time to onset of FEV1 >100mL
Timeframe: Change in FEV1 >100mL from pre-dose on Days 1 and 14
Secondary (9)
Pharmacokinetics - Cmax
Pharmacokinetics - AUC
Pharmacokinetics - Tmax
Treatment-emergent adverse events (TEAEs)
Blood Pressure
Show 4 moreShow less
Heart Rate
12-lead ECG - QT Interval corrected for Heart Rate Using Fridericia's Formula (QTcF)
Clinical laboratory - Hematology
Clinical laboratory - Blood Chemistry
Arms and interventions
AERO-001 low doseExperimental
AERO-001 medium doseExperimental
AERO-001 high doseExperimental
AERO-002 low doseExperimental
AERO-002 medium doseExperimental
AERO-002 high doseExperimental
AERO-007Experimental
PlaceboPlacebo comparator
Drugs: AERO-001, AERO-002, AERO-007
Sites
2 sites in 1 country